NCT06349837 2025-12-17
Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors
Sichuan University
Phase 1 Recruiting
Sichuan University
The Affiliated Hospital of Xuzhou Medical University
Ruijin Hospital
University Hospital, Basel, Switzerland
Tianjin Medical University Cancer Institute and Hospital